Assessment of factors that influence physician decision making regarding medication use in patients with dementia at the end of life

International Journal of Geriatric Psychiatry

Volumn 29, Issue 3, 2014, Pages 281-290

  Parsons, Carole ^a   McCorry, Noleen ^b   Murphy, Kevin ^c   Byrne, Stephen ^c   O'Sullivan, David ^c   O'Mahony, Denis ^c   Passmore, Peter ^d   Patterson, Susan ^e   Hughes, Carmel ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Marie Curie Cancer Care   (United Kingdom)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e HEALTH AND SOCIAL CARE BOARD   (United Kingdom)

Author keywords

decision making; dementia; end of life; medication

Indexed keywords

DECISION MAKING; DEMENTIA; END OF LIFE; MEDICATION;

ADULT; DECISION MAKING; DEMENTIA; FAMILY PRACTICE; FEMALE; HOSPITALS; HUMANS; IRELAND; LOGISTIC MODELS; MALE; MIDDLE AGED; NORTHERN IRELAND; PATIENT-CENTERED CARE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; TERMINAL CARE;

EID: 84893944740     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4006     Document Type: Article

References (77)

1. Ballard C, Margallo-Lana M, Jusczak E, et al,. 2005. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: a randomised double blind placebo controlled trial. BMJ 330: 874.
2. Ballard C, Hanney ML, Theodoulou M, et al,. 2009. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8: 151-157.
3. Birks J,. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1: CD005593. DOI: 10.1002/14651858.CD005593.
4. Blass DM, Black BS, Phillips H, et al,. 2008. Medication use in nursing home residents with advanced dementia. Int J Geriatr Psychiatry 23: 490-496.
5. de Boer ME, Hertogh CMPM, Dröes RM, et al,. 2010 Advance directives in dementia: issues of validity and effectiveness. Int Psychogeriatr 22: 201-208.
6. Bradley MC, Fahey T, Cahir C, et al,. 2012. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol 68: 1425-1433.
7. Byrne M, Doherty S, McGee HM, et al,. 2010. General practitioner views about discussing sexual issues with patients with coronary heart disease: a national survey in Ireland. BMC Fam Pract 11: 40.
8. Chen JH, Lamberg JL, Chen YC, et al,. 2006. Occurrence and treatment of suspected pneumonia in long-term care residents dying with advanced dementia. J Am Geriatr Soc 54: 290-295.
9. Chen Y, Briesacher BA, Field TS, et al,. 2010. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 170: 89-95.
10. Coleman AME,. 2012. End-of-life issues in caring for patients with dementia: the case for palliative care in management of terminal dementia. Am J Hosp Palliat Care 29: 9.
11. Congedo M, Causarano RI, Albert F, et al,. 2010. Ethical issues in end of life treatments for patients with dementia. Eur J Neurol 17: 774-779.
12. Cruz-Jentoft AJ, Boland B, Rexach L,. 2012. Drug therapy optimization at the end of life. Drugs Aging 29: 511-521.
13. Currow DCB, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM,. 2007. Prescribing in palliative care as death approaches. J Am Geriatr Soc 55: 590-595.
14. D'Agata E, Mitchell SL,. 2008. Patterns of antimicrobial use among nursing home residents with advanced dementia. Arch Intern Med 168: 357-362.
15. Daiello LA, Ott BR, Lapane KL, et al,. 2009. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 7: 74-83.
16. Department of Health. 2009. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services by Professor Sube Banerjee.
17. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD,. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58: 427-433.
18. Edwards PJ, Roberts I, Clarke MJ, et al,. 2009. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev (3). Art. No.: MR000008. DOI: 10.1002/14651858.MR000008.pub4
19. Eisemann M, Richter J, Bauer B, et al,. 1999. Physicians' decision-making in incompetent elderly patients: a comparative study between Austria, Germany (East, West), and Sweden. Int Psychogeriatr 11: 313-324.
20. Evers MM, Purohit D, Perl D, et al., 2002. Palliative and aggressive end-of-life care for patients with dementia. Psychiatr Serv 53: 609-613.
21. Farber NJ, Simpson P, Salam T, et al,. 2006. Physicians' decisions to withhold and withdraw life-sustaining treatment. Arch Intern Med 166: 560-564.
22. Gill SS, Bronskill SE, Normand SLT, et al,. 2007. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146: 775-786.
23. Givens JL, Jones RN, Shaffer ML, Kiely DK, Mitchell SL,. 2010. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Int Med 170: 1102-1107.
24. Goodman C, Evans C, Wilcock J, et al,. 2010. End of life care for community dwelling older people with dementia: an integrated review. Int J Geriatr Psychiatry 25: 329-337.
25. Harris D,. 2007. Forget me not: palliative care for people with dementia. Postgrad Med J 83: 362-366.
26. Helton MR, van der Steen JT, Daaleman TP, et al,. 2006. A cross-cultural study of physician treatment decisions for demented nursing home patients who develop pneumonia. Ann Fam Med 4: 221-227.
27. Herrmann N, Gauthier S,. 2008. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMA J 179: 1279-1287.
28. Herrmann N, Gauthier S, Lysy PG,. 2007a. Clinical practice guidelines for severe Alzheimer's disease. Alzheimers Dement 3: 385-397.
29. Herrmann N, Gill SS, Bell CM, et al,. 2007b. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 55: 1517-1523.
30. Hinkka H, Kosunen E, Lammi U, et al,. 2002. Decision making in terminal care: a survey of Finnish doctors' treatment decisions in end-of-life scenarios involving a terminal cancer and a terminal dementia patient. Palliat Med 16: 195-204.
31. Holmes HM,. 2009. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 85: 103-107.
32. Holmes C, Wilkinson D, Dean C, et al,. 2004. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63: 214-219.
33. Holmes HM, Sachs GA, Shega JW, et al,. 2008. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc 56: 1306-1311.
34. Howard R, McShane R, Lindesay J, et al,. 2012. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366: 893-903.
35. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D,. 2011. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 343: d4065.
36. Lee SP, Bain KT, Maio V,. 2007. Appropriate discontinuation of medications at the end of life: a need to establish consensus criteria. Am J Med Qual 22: 393-394.
37. Lövheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y,. 2006. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 18: 713-726.
38. Maddison AR, Fisher J, Johnston G,. 2011. Preventive medication use among persons with limited life expectancy. Prog Palliat Care 19: 15-21.
39. Margallo-Lana M, Swann A, O'Brien J, et al,. 2001. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 16: 39-44.
40. McIlfatrick S, Keeney S, McKenna H, et al,. 2013 Investigating the role of the general practitioner in cancer prevention: a mixed methods study. BMC Fam Pract 14: 58.
41. McLean S, Sheehy-Skeffington B, O'Leary N, O'Gorman A,. 2013. Pharmacological management of co-morbid conditions at the end of life: is less more? Ir J Med Sci 182: 107-112.
42. Mitchell SL, Kiely DK, Hamel MB,. 2004. Dying with advanced dementia in the nursing home. Arch Intern Med 164: 321-326.
43. Nakanishi M, Honda T,. 2009. Processes of decision making and end-of-life care for patients with dementia in group homes in Japan. Arch Gerontol Geriatr 48: 296-299.
44. Nijk RM, Zuidema SU, Koopmans RTCM,. 2009. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int Psychogeriatr 21: 485-493.
45. Nuffield Council of Bioethics. 2009. Dementia: ethical issues.
46. O'Mahony D, O'Connor MN,. 2011. Pharmacotherapy at the end of life. Age Ageing 40: 419-422.
47. Okazaki T, Furukawa K, Kubo H, et al,. 2006. Paralytic ileus after discontinuation of cholinesterase inhibitor. J Am Geriatr Soc 54: 1620-1621.
48. Onwuteaka-Philipsen BD, Fisher S, Cartwright C, et al,. 2006. End-of-life decision making in Europe and Australia: a physician survey. Ann Intern Med 166: 921-929.
49. Parsons C, Hughes CM, Passmore AP, Lapane KL,. 2010. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging 27: 435-449.
50. Pazart L, Vidal C, Faivre Chalon D, et al,. 2011. "Card sorting": a tool for research in ethics on treatment decision-making at the end of life in Alzheimer patients with a life threatening condition. BMC Palliat Care 10: 4.
51. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS,. 2004. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr 16: 61-74.
52. Richter J, Eisemann M, Zgonnikova E,. 2001. Doctors' authoritarianism in end-of-life treatment decisions: a comparison between Russia, Sweden and Germany. J Med Ethics 27: 186-191.
53. Richter J, Eisemann M, Zgonnikova E,. 2002. Doctors' attitudes and end-of-life decisions in the elderly: a comparative study between Sweden, Germany and Russia. Arch Gerontol Geriatr 34: 107-115.
54. Robertson J, Treloar CJ, Sprogis A, Henry DA,. 2003. The influence of specialists on prescribing by GPs. A qualitative study. Aust Fam Physician 32: 573-576.
55. Robinson L, Hughes J, Daley S, et al,. 2005. End-of-life care and dementia. Rev Clin Gerontol 15: 135-148.
56. Rochon PA, Stukel TA, Bronskill SE, et al,. 2007. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 167: 676-683.
57. Rurup ML, Onwuteaka-Philipsen BD, Pasman HRW, Ribbe MW, van der Wal G,. 2006. Attitudes of physicians, nurses, and relatives towards end-of-life decisions concerning nursing home patients with dementia. Patient Educ Couns 61: 372-380.
58. Scott I, Jayathissa S,. 2010. Quality of drug prescribing in older patients: is there a problem and can we improve it? Int Med J 40: 7-18.
59. Seale C,. 2009a. End-of-life decisions in the UK involving medical practitioners. Palliat Med 23: 198-204.
60. Seale C,. 2009b. Hastening death in end-of-life care: a survey of doctors. Soc Sci Med 69: 1659-1666.
61. Selbaek G, Kirkevold O, Engedal K,. 2007. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 22: 843-849.
62. Shega JW, Ellner L, Lau DT, Maxwell TL,. 2009. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med 12: 779-783.
63. Simpson S, Beavis D, Leddy A, Ball S, Johnson I,. 2005. Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. Psychiatr Bull R Coll Psychiatr 29: 410-412.
64. Singh S, Dudley C,. 2003. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 18: 282-284.
65. van der Steen JT, Muller MT, Ooms ME, et al,. 2000. Decisions to treat ot not to treat pneumonia in demented psychogeriatric nursing home patients: development of a guideline. J Med Ethics 26: 114-120.
66. van der Steen JT, Ooms ME, Adèr HJ, et al,. 2002a. Withholding antibiotic treatment in pneumonia patients with dementia: a quantitative observational study. Arch Intern Med 162: 1753-1760.
67. van der Steen JT, Ooms ME, van der Wal G, Ribbe MW,. 2002b. Pneumonia: the demented patient's best friend? Discomfort after starting or withholding antibiotic treatment. J Am Geriatr Soc 50: 1681-1688.
68. van der Steen JT, Kruse RL, Ooms ME, et al,. 2004. Treatment of nursing home residents with dementia and lower respiratory tract infection in the United States and the Netherlands: an ocean apart. J Am Geriatr Soc 52: 691-699.
69. van der Steen JT, Ooms ME, van der Wal G, et al,. 2005. Withholding or starting antibiotic treatment in patients with dementia and pneumonia: prediction of mortality with physicians' judgment of illness severity and with specific prognostic models. Med Decis Making 25: 210-221.
70. de Vries CS, van Diepen NM, Tromp TF, et al,. 1996. Auditing GPs' prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. Eur J Clin Pharmacol 50: 349-352.
71. st century (MOXXI): effectiveness of computerised decision-making support in reducing inappropriate prescribing in primary care. CMAJ 169: 549-556.
72. Thé AM, Pasman R, Onwuteaka-Philipsen B, et al,. 2002. Withholding the artificial administration of fluids and food from elderly patients with dementia: ethnographic study. Br Med J 325: 1326-1330.
73. Thompson T, Barbour R, Schwartz L,. 2003. Adherence to advance directives in critical care decision making: vignette study. Br Med J 327: 1011.
74. Thorpe C, Ryan B, McLean SL, et al,. 2008 How to obtain excellent response rates when surveying physicians. Fam Pract 26: 65-68.
75. Tjia J, Rothman MR, Kiely DK, et al,. 2010. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc 58: 880-888.
76. Vollrath AM, Sinclair C, Hallenbeck J,. 2005. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 8: 876-881.
77. Weschules DJ, Maxwell Tl, Shega JW,. 2008. Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrolees with a primary diagnosis of dementia. J Palliat Med 11: 738-745.